By Reuters Staff
2 Min Read
BENGALURU (Reuters) - India’s Cadila Healthcare Ltd has received restricted emergency use approval from local regulators to use a Hepatitis C drug as a treatment for moderate COVID-19 in adults, the drugmaker said on Friday.
The approval follows promising results from a late-stage study of the drug, and comes in the middle of a massive wave of COVID-19 cases in India, which has overwhelmed its health system and left many hospitals short of critical oxygen supplies.
Cadila said patients given its therapy in clinical trials had shown lesser need for supplemental oxygen, which is given to seriously ill COVID-19 patients to increase its supply in the blood and lungs.